KMDA 6-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

KMDA ▲ +0.73% at T+20d

LONG call ✓ call won +0.73% · α vs SPY -9.94% · entry $8.22 → $8.28

Next anchor: T+60d in 13d

Currently $7.24 · -11.92% from $8.22 entry

Entry anchored
Mar 25, 03:59 PM ET
via Databento tick

T+1d

-0.85%

call -0.85% · α +0.83%

$8.15

settled 3mo ago

T+5d

+3.04%

call +3.04% · α +1.41%

$8.47

settled 2mo ago

T+20d

+0.73%

call +0.73% · α -9.94%

$8.28

settled 7w ago

T+60d

—

call — · α —

—

in 13d

Price Chart

Loading chart...

Executive Summary

Kamada Ltd. announced FDA approval of its plasma collection center in San Antonio, Texas, enabling the facility to commence commercial sales of normal source plasma. The center has an annual collection capacity of approximately 50,000 liters and is expected to generate $8 million to $10 million in annual revenue at full capacity, supporting both normal and specialty plasma collection.

Actionable Insight

Traders should monitor ramp-up timing toward full capacity and future EMA approval prospects, which could expand market access. The new center strengthens Kamada’s vertical integration and revenue diversification in the high-demand plasma market.

Key Facts

FDA has approved Kamada's plasma collection center in San Antonio, Texas.
The facility has a planned annual collection capacity of ~50,000 liters of plasma.
Estimated annual revenue contribution of $8 million to $10 million at full capacity from normal source plasma sales.
San Antonio center is anticipated to be one of the largest specialty plasma collection centers in the U.S.
Kamada now owns three FDA-approved plasma collection centers in Texas (Beaumont, Houston, San Antonio).
Company plans to seek European Medicines Agency (EMA) approval for the San Antonio site.

Financial Impact

Adds $8M to $10M in annual revenue at full capacity, representing a meaningful expansion in Kamada's plasma-derived revenue stream.

revenuecapacityplasma supply

Risk Factors

Revenue projections are forward-looking and dependent on achieving full operational capacity.
Geopolitical risks in the Middle East may impact operations in Israel.
Regulatory delays for EMA approval could limit international expansion.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001213900-26-034342
Document: ea0283431-6k_kamada.htm	0001213900-26-034342
Document: 0001213900-26-034342-index-headers.html	0001213900-26-034342
Document: 0001213900-26-034342-index.html	0001213900-26-034342
Document: 0001213900-26-034342.txt	0001213900-26-034342

7 reports for KMDA

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+5▲ +3.31%May 13, 2026

Filters

Reports for KMDA — sortable, filterable
	Type				Now
Jun 1, 2026 8d ago	6-K BULLISH ★ 5/10	$7.70 $7.17	▼ −6.88%	▼ −4.13%	$7.24 (−5.97%)
May 13, 2026 27d ago	Press Release BEARISH ★ 7/10	$7.86 $7.60	▲ +3.31%	▲ +2.15%	$7.24 (+7.89%)
Mar 31, 2026 10w ago	6-K NEUTRAL ★ 3/10	$8.34 $8.47	▲ +1.56%	▼ −2.39%	$7.24 (−13.19%)
Mar 26, 2026 10w ago	6-K BULLISH ★ 7/10	$8.22 $8.47	▲ +3.04%	▲ +1.41%	$7.24 (−11.92%)
Mar 26, 2026 10w ago	Press Release BULLISH ★ 7/10	$8.22 $8.47	▲ +3.04%	▲ +1.41%	$7.24 (−11.92%)
Mar 11, 2026 12w ago	Press Release BULLISH ★ 8/10	$8.30 $8.34	▲ +0.47%	▲ +2.66%	$7.24 (−12.76%)
Mar 11, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$8.30 $8.34	▲ +0.47%	▲ +2.66%	$7.24 (−12.76%)

US Market Status

Market Closed — Opens Thu (10h 7m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access